Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716133 | 0.83 | ADORA2B (0.38) | ADORA2BALOX15LMNASMN1; SMN2MEN1 | |
| SCHEMBL9972908 | 0.76 | KMT2A (0.44) | ADORA2BLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1689594 | 0.76 | TRPA1 (0.34) | TP53ALOX15TRPA1 | |
| SCHEMBL13834428 | 0.73 | ALDH1A1 (0.36) | ADORA2BTP53LMNASMN1; SMN2MAPT | |
| SCHEMBL1689535 | 0.71 | ADORA2B (0.40) | ADORA2BALOX15LMNAKMT2ATAS2R14 | |
| SCHEMBL13190508 | 0.68 | ALOX15 (0.42) | ADORA2BALOX15LMNATAS2R14MAPT | |
| SCHEMBL14981131 | 0.67 | TNF (0.44) | TP53ALOX15LMNASMN1; SMN2TAS2R14 | |
| SCHEMBL14981101 | 0.66 | ALDH1A1 (0.36) | TP53ALOX15LMNASMN1; SMN2MEN1 | |
| SCHEMBL9972885 | 0.64 | KDM4E (0.41) | ADORA2BLMNAKMT2AKDM4EALDH1A1 | |
| SCHEMBL14972716 | 0.63 | KDM4E (0.36) | ADORA2BTP53KMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575178-B2 | Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-11-05 | — | — | US | disclosed |
| EP-2411397-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-20120010223-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010223-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | ADORA2B 133/4885TP53 1503/4885ALOX15 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.